STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in fireside chats and investor meetings at upcoming investor conferences in Miami, FL:

  • The Leerink Partners Global Biopharma Conference, the fireside chat will take place on Tuesday, March 11, 2025, at 9:20 AM ET.
  • The Barclays 27th Annual Global Healthcare Conference, the fireside chat will take place on Wednesday, March 12, 2025, at 3:30 PM ET.

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

Evolus

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Latest SEC Filings

EOLS Stock Data

477.72M
52.29M
11.81%
91.06%
17.98%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH